Document is current
Any future updates will be listed below
-
Authors
Matsuda, Satoru
Irino, Tomoyuki
Kawakubo, Hirofumi
Takeuchi, Masashi
Nishimura, Erika
Hisaoka, Kazuhiko
Sano, Junichi
Kobayashi, Ryota
Fukuda, Kazumasa
Nakamura, Rieko
Takeuchi, Hiroya
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 9 August 2022
Accepted: 10 January 2023
First Online: 2 March 2023
Disclosure
: Yuko Kitagawa has received grants and personal fees from Asahi Kasei Pharma Corporation, Ono Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Factory, Inc., Nippon Covidien Inc., Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, and Kaken Pharmaceutical Co., Ltd; personal fees from AstraZeneca K.K., Ethicon Inc., Olympus Corporation, Shionogi Co., Ltd, Bristol-Myers Squibb K.K., MSD K.K., Smith & Nephew K.K., ASKA Pharmaceutical Co., Ltd, Miyarisan Pharmaceutical Co., Ltd, Toray Industries, Inc., Daiichi Sankyo Co., Ltd, Chugai Foundation for Innovative Drug Discovery Science, and Nippon Kayaku Co., Ltd; and grants from Yakult Honsha Co. Ltd, Otsuka Pharmaceutical Co., Ltd, Tsumura & Co., Sumitomo Pharma Co., Ltd, EA Pharma Co., Ltd, Eisai Co., Ltd, Kyouwa Hakkou Kirin Co., Ltd, Medicon Inc., Takeda Pharmaceutical Co., Ltd, and Teijin Pharma Ltd. Satoru Matsuda, Tomoyuki Irino, Hirofumi Kawakubo, Masashi Takeuchi, Erika Nishimura, Kazuhiko Hisaoka, Junichi Sano, Ryota Kobayashi, Kazumasa Fukuda, Rieko Nakamura, and Hiroya Takeuchi have no conflicts of interest to declare.
